Press releases
- Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
- Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
- Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
- Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
- Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
- Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
More ▼
Key statistics
As of last trade, Gossamer Bio Inc (4GB:DUS) traded at 0.602, 36.79% above the 52 week low of 0.4401 set on Oct 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.6215 |
---|---|
High | 0.6215 |
Low | 0.602 |
Bid | 0.6035 |
Offer | 0.6355 |
Previous close | 0.6165 |
Average volume | 622.22 |
---|---|
Shares outstanding | 226.22m |
Free float | 219.54m |
P/E (TTM) | -- |
Market cap | 154.58m USD |
EPS (TTM) | -1.05 USD |
Data delayed at least 15 minutes, as of May 21 2024 11:31 BST.
More ▼